Trends in development of the influenza vaccine with broader cross-protection

Acta Virologica

Volumn 54, Issue 1, 2010, Pages 7-19

  Stropkovska A ^a   Janulikova J ^a   Vareckova E ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Adjuvants; Conserved antigens; Immune response; Influenza a virus; Live vaccine; Vaccine efficacy

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; CHOLERA TOXIN B SUBUNIT; DNA VACCINE; EPITOPE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEMBRANE PROTEIN; MEMBRANE PROTEIN M2; MIFAMURTIDE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS PROTEIN; VIRUS SIALIDASE; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; CROSS PROTECTION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INNATE IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS MORPHOLOGY; ANIMAL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; IMMUNOLOGY; INFLUENZA; VIROLOGY;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS PROTECTION; DRUG DESIGN; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, MOLECULAR;

EID: 77952318056     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2010_01_7     Document Type: Review

References (123)

1. Ada GL, Jones PD. (1986) The immune response to influenza infection. Curr. Top. Microbial. Immunol. 128, 1-54.
2. Arnon R. (2006) A novel approach to vaccine design Epitope-based vaccines. Bti. 18, 10-13.
3. Becht H, Huang RT, Fleischer B, Boschek CB, Rott R. (1984) Immunogenic properties of the small chain HA2 of the haemagglutinin of influenza viruses. J. Gen. Virol. 65, 173-183.
4. Ben-Yedidia T, Arnon R. (2005) Towards an epitope-based vaccine for influenza. Human vaccine 1, 95-101.
5. Brandtzaeg P, Krajci P, Lamm ME, Kaetzl CZ. (1994) Epithelial and hepatobiliary transport of polymeric immunoglobulins. In Ogra PL, Lamm ME, McGhee JR, Mestecky J, Strober W, Bienenstock J (Eds) Handbook of Mucosal Immunology. Academic Press, San Diego, California, pp. 113-126.
6. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. (2007) Influenza-like particles elicit broader immune responses than whole virion inactivated influenza virus recombinant hemagglutinin. Vaccine 25, 3871-3878.
7. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLOS 1, e1501.
8. Chen J, Wharton SA, Weisserhorn W, Calder L, Hughson FM, Skehel JJ, Wiley DC. (1995) A soluble domain of the membrane-anchoring chain of the influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low pH-induced conformation. Proc. Natl. Acad. Sci. USA 92, 12205-12209.
9. Chen D, Endres RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y, Payne LG. (2000) Epidermal immunization by a nedele-free powder delivery technology Immunogenicity of influenza vaccine and protection in mice. Nat. Med. 6, 1187-1190.
10. Chen, W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S, O'Neill R, Schickli J, Palese P, Henklein P, Bennink JR, Yewdell JW. (2001) A novel influenza A virus mitochondrial protein that induces cell death, Nat. Med. 7, 1306-1312.
11. Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, Ng MH, Shih JW, Peiris JS, Guan Y, Chen H and Xia N. (2009) Broad cross-protection agianst H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J. Infect. Dis. 199, 49-58.
12. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. (1974) Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis. 129, 411-420.
13. Couch RB, Kasel JA. (1983) Immunity to influenza in man. Annu. Rev. Microbiol. 37,529-49.
14. Daniels RS, Downie JC, Hay AJ, Knossow M, Skehel JJ, Wang ML, Wiley DC. (1985) Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell 40, 431-439.
15. De Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. (2007) Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 26, 119.
16. De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Löwenadler B, Lycke N, Jou WM, Saelens X. (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24, 6597-6601.
17. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X. (2008) An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J. Biol. Chem. 283,11382-11387.
18. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531.
19. Durrer P, Gluck U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Gluck R. (2003) Mucosal antibody responses induced with a nasal virosome-based influenza vaccine. Vaccine 21, 4328-4334.
20. Edwards MJ, Dimmock NJ. (2000) Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 278, 423-435.
21. Edwards MJ, Dimmock NJ. (2001) A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J. Gen. Virol. 82, 387-1395.
22. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251.
23. Elton D, Digard P, Tiley L, Ortin J. (2006) Structure and function of the influenza virus RNP. In Kawaoka Y (Eds) Influenza Virology, Current Topics. Caister Academic Press, Norfolk, England, pp. 1-36.
24. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, Adler-Moore JP, Fujii G. (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24, 5158-5168.
25. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW. (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22, 2993-3003.
26. Ferko B, Stasakova J, Romanova J, Kittel C, Sereinig S, Katinger H, Egorov A.. (2004) Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J. Virol. 78, 13037-13045.
27. Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, Egorov A. (2006) Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J. Virol. 80,11621-11627.
28. Fiers W, Neirynck S, Deroo T, Saelens X, Jou WM. (2001) Soluble recombinant influenza vaccines. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 1961-1963.
29. Fislová T, Sládková T, Gocník M, Mucha V, Varečková E, Kostolanský F. (2005) Differences in antibody responses of mice to intranasal or intraperitoneal immunization with influenza A virus and vaccination with subunit influenza vaccine. Acta Virol. 49, 243-250.
30. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. (1999) Rescue of influenza A virus from recombinant DNA. J. Virol. 3, 9679-9682.
31. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Rimmelzwaan GF, Olsen B, Osterhaus AD. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79, 2814-2828.
32. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T. (1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324-330.
33. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ.. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 10, 197-201.
34. Gerhard W. (2001) The role of the antibody response in influenza virus infection. Curr Top Microbiol. Immunol. 260, 171-190.
35. Gerhard W, Mozdzanowska K, Zharikova D. (2006) Prospects for universal influenza virus vaccine. Emerg. Inf. Dis. 12, 569-574.
36. Gillim-Ross L, Subbarao K. (2006) Emerging respiratory viruses challenges and vaccine strategies. Clin. Microbiol. Rev. 19, 614-636.
37. Gocník M, Fislová T, Sládková T, Mucha V, Kostolanský F, Varečková E. (2007) Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J. Gen. Virol. 88, 951-955.
38. Gocník M, Fislová T, Mucha V, Sládková T, Russ G, Kostolansky F, Varečková E. (2008) Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J. Gen. Virol. 89, 958-967.
39. Graves PN, Schulman JL, Young JF, Palese P. (1983) Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin unmasking of cross-reactive HA2 determinants. Virology 126, 106-116.
40. Grebe KM, Yewdell JW, Bennink JR. (2008) Heterosubtypic immunity to influenza A virus where do we stand? Microbes Infect. 10, 1024-1029.
41. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S. (2006) Development of adenoviral-vector-based pandemic influenza vaccine againts antigenically distinct human H5N1 strains in mice. Lancet 367, 475-481.
42. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. (2002) Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20, 3165-3170.
43. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460, 1021-1025.
44. Johansson BE, Bucher DJ, Kilbourne ED. (1989) Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 63, 1239-1246.
45. Johansson BE. (1999) Immunization with influenza A hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17, 2073-2080.
46. Kang SM, Pushko P, Bright RA, Smith G, Compans RW. (2009) Influenza virus-like particles as pandemic vaccine. Curr. Top. Microbiol. Immunol. 333, 269-289.
47. Katz JM, Garg S, Sambhara S. (2006) Influenza vaccines current and future strategies. In Kawaoka Y (Ed.) Influenza Virology, Current Topics. Caister Ac Press, Norfolk, England, pp. 203-228.
48. Kilbourne ED, Pokorny BA, Johansson B, Brett I, Milev Y, Matthews JT. (2004) Protection of mice with recombinant influenza virus neuraminidase. J. Infect. Dis. 189, 459-461. doi:10.1086/381123.
49. Kostolanský F, Mucha V, Slováková R, Varečková E. (2002) Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide. Acta Virol. 46, 229-236.
50. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR. (2008) Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 197,1643-1652.
51. Lewis DB. (2006) Avian Flu to Human Influenza. Annu. Rev. Med. 57, 139-154.
52. Lim AP, Wong SK, Chan AH, Chan CE, Ooi EE, Hanson BJ. (2008) Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. Virol. J. 5, 80.
53. Lipatov AS, Gitelman AK, Smirnov YA. (1997) Prevention and treatment of lethal influenza A virus bronchopneumonia in mice by monoclonal antibody against hemagglutinin stem region. Acta Virol. 41, 337-340.
54. Luke CJ, Subbarao K. (2006) Vaccines for pandemic influenza. Emerg. Infect. Dis. 12, 66-72.
55. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101, 5598-55603.
56. Macken C, Lu H, Goodman J, Boykin L. (2001) The value of a database in surveillance and vaccine selection. In Osterhaus ADME, Cox N, Hampson AW. Amsterdam (Eds) Options for the Control of Influenza IV. Elsevier Science, pp. 103-106.
57. Martin K, Helenius A. (1991) Nuclear transport of influenza virus ribonucleoproteins the viral matrix protein (M1) promotes export and inhibits import. Cell 67, 117-130. doi:10.1016/0092-8674(91)90576-K.
58. Mbawuike IN, Wyde PR. (1993) Induction of CD8+ cytotoxic T cells by immunization with killed influenza virus and effect of cholera toxin B subunit. Vaccine 11, 1205-1213.
59. Michaelis M, Doerr HW, Cinatl J Jr. (2009) Novel Swine-origin influenza A virus in humans another pandemic knocking at the door. Med. Microbiol. Immunol. 198, 175-183.
60. Mikulášová A, Varečková E, Fodor E. (2000) Transcription and replication of the influenza A virus genome. Acta Virol. 44, 273-282.
61. Mitchell JA, Green TD, Bright RA, Ross TM. (2003) Induction of heterosubtypic imunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21, 902-914.
62. Murphy BR, Clements ML. (1989) The systemic and mucosal immune response of humans to influenza A virus. Curr. Top. Microb. Immunol. 146, 07-116.
63. Nash T. (1998) Immunity to viruses. In Roitt I, Brostoff J, Male D (Eds) Immunology. 5th ed., Mosby, London, pp. 221-228.
64. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. (1999) A universal influenza a vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1119-1120.
65. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96, 9345-9350.
66. Neumann G, Kawaoka Y. (2002) Generation of influenza A virus from cloned cDNAs-historical perspective and outlook for the new millenium. Rev. Med. Virol. 12, 13-30.;.
67. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, Nakajima K. (1991) Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influeChen J, Whartonnza A viruses. Virology 182, 475-485.
68. Okuno Y, Isegawa Y, Sasao F, Ueda S. (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552-2558.
69. Palese P. (2006) Making better influenza virus vaccines? Emerg. Infect. Dis. 12, 61-65.
70. Palese P, García-Sastre A. (2002) Influenza vaccines present and future. J. Clin. Invest. 110, 9-13.
71. Palese P, Shaw ML. (2007) Orthomyxoviridae The viruses and their replication In Knipe DM, Howley PM (Eds) Fields Virology. 5th ed., Lippincott Wiliams and Wilkins, pp. 1647-1689.
72. Palladino G, Mozdzanowska K, Washko G, Gerhard W. (1995) Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 69, 2075-2081.
73. Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, Goutama M, Kwang J. (2009) Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 83, 2553-2562.
74. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. (2005) Influenza viruslike particles comprised of the HA, NA and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23, 5751-5759.
75. Richardson JC, Akkina RK. (1991) NS2 protein of influenza virus is found in purified virus and phosforylated in infected cells. Arch. Virol. 116, 69-80.
76. Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, MorokuttiA, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U, Bergmann M, Sachet M, Balasingam S, Mann A, Oxford J, Slais M, Kiselev O, Muster T, Egorov A.. (2009) Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1influenza vaccine. PLoS One 19; e5984.
77. Ruigrok RWH. (1998) Structure of Influenza A, B and C Viruses. In Nicholson KG, Webster RG, Hay AJ (Eds) Textbook of Influenza. Blackwell cience, GB, 29-48.
78. Russ G, Poláková K, Kostolanský F, Styk B, Vančiková M. (1987) Monoclonal antibodies to glycopeptides HA1 and HA2 of influenza virus hemagglutinin. Acta Virol. 31, 374-386.
79. Sanchez-Fauquier A, Villanueva N, Melero JA. (1987) Isolation of cross-reactive, subtype-specific monoclonal antibodies against influenza virus HA1 and HA2 hemagglutinin subunits. Arch. Virol. 97, 251-265.
80. Sandrock Ch, Kelly T. (2007) Clinical review Update of avian influenza A infections in humans. Critical Care 11, 1-9 d.
81. Seo SH, Webster RG. (2002) Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. Virol. 76, 1071-1076.
82. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, Lindstrom S, Gubareva LV, Deyde V, Garten RJ, Harris M, Gerber S, Vagasky S, Smith F, Pascoe N, Martin K, Dufficy D, Ritger K, Conover C, Quinlisk P, Klimov A, Bresee JS, Finelli L. (2009) Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N. Engl. J. Med. 18; 2616-2625.
83. Skehel JJ, Bayley PM, Brown EB, Martin SR, Waterfield MD, White JM, Wilson I.A, Wiley DC. (1982) Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc. Natl. Acad. Sci. USA 79, 968-972.
84. Skehel JJ, Wiley DC. (2000) Receptor binding and membrane fusion in virus entry The influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569.
85. Smirnov YA, Lipatov SA, Gitelman AK, Claas ECJ, Osterhaus ADME. (2000) Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem. Arch. Virol. 145, 1733-1741.
86. Smith GJ, Bahl J, Vijaykrishna D, Zhang J, Poon LL, Chen H, Webster RG, Peiris JS, Guan Y. (2009) Dating the emergence of pandemic influenza viruses. Proc. Natl. Acad. Sci. USA 106, 11709-11712.
87. Squarcione S, Sgricia S, Biasio LR, Perinetti E. (2003) Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21, 1268-1274.
88. Steinhauer DA, Skehel JJ. (2002) Genetics of influenza viruses. Annu. Rev. Genet. 36, 305-332.
89. Stropkovská A, Mucha V, Fislová T, Gocník M, Kostolanský F, Varečková E. (2009) Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin. Acta Virol. 53, 15-20. doi:10.4149/av_2009_01 _15.
90. Styk B, Russ G, Poláková K. (1979) Antigenic glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. IV. Immunogenic properties of separated haemagglutinin glycopolypeptides. Acta Virol. 23, 9-20.
91. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273.
92. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. (2003) Intranasal immunisation with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza a virus infection in mice. Vaccine 21, 3212-3218.
93. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, García-Sastre A, Palese P. (2000) Influenza A nad B viruses expressing altered NS1 proteins A vaccine approach. Proc. Natl. Acad. Sci. USA 97, 4309-4314.
94. Tamura S, Samegai Y, Kurata H, Nagamine T, Aizawa C, Kurata T. (1988) Protection against influenza virus infection by vaccine inoculated intranassaly with cholera toxin B subunit. Vaccine 6, 409-413.
95. Tamura S, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, Suzuki Y, Nagamine T, Kawahara K, Danbara H, and et al.. (1994) Synergistic action of cholera toxin B subunit) and a trace mount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12, 419-426.
96. Tamura S, Tanimoto T, Kurata T. (2005) Mechanisms of Broad Cross-Protection Provided by Influenza Virus Infection and Their Application to Vaccines. Jpn. J. Infect. Dis. 58, 1196-1198.
97. Taylor PM, Askonas BA. (1986) Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 58, 417-420.
98. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3, e3942.
99. Tkáčová M, Varečková E, Baker IC, Love JM, Ziegler T. (1997) Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses. J. Clin. Microbiol. 35, 1196-1198.
100. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH. (1993) Heterogous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1691-1692.
101. Ulmer JB. (2002) Influenza DNA vaccines. Vaccine 20 (Suppl. 2), 74-76.
102. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen D, Marks D, Elmets CA, Tang, DC. (2005) Safety and immunogenicity of adenovirus-vestored nasal and epicutaneous influenza vaccines in humans. Vaccine 23, 1029-1036.
103. Vanlandschoot P, Beirnaert E, Barrère B, Calder L, Millar B, Wharton S, Jou WM, Fiers W. (1998) An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus. J. Gen. Virol. 79, 1781-1791.
104. Varečková E, Cox N, Klimov A. (2002) Evaluation of subtype specificity of monoclonal antibodies raised against H1 and H3 subtypes of human influenza A virus hemagglutinins. J. Clin. Microbiol. 40, 2220-2223.
105. Varečková E, Mucha V, Wharton SA, Kostolanský F. (2003a) Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies. Arch. Virol. 148, 469-486.
106. Varečková E, Wharton SA, Mucha V, Gocník M, Kostolanský F. (2003b) A monoclonal antibody specific to the HA2 glycoprotein of influenza A virus hemagglutinin that inhibits its fusion activity reduces replication of the virus. Acta Virol. 47, 229-236.
107. Varečková E, Mucha V, Kostolanský F, Gubareva LV, Klimov A. (2008) HA2-specific monoclonal antibodies as tools for differential recognition of influenza A virus antigenic subtypes. Virus Res. 132, 181-186.
108. Wang TT and Palese P. (2009) Universal epitopes of influenza virus hemagglutinins? Nat. Struct. Mol. Biol. 16, 233-234.
109. Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. (2002a) Immunogenicity and protective efficacy of replicationincompetent influenza virus-like particles. J. Virol. 76, 767-773.
110. Watanabe T, Watanabe S, Kida H, Kawaoka Y. (2002b) Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology 299, 266-270.
111. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. (1988) Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333, 426-431.
112. Wesley RD, Tang M, Lager KM. (2004) Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 22, 3427-3434.
113. White JM, Hoffman LR, Arevalo JH, Wilson IA. (1997) Attachment and entry of influenza virus into host cells. Pivotal roles of hemagglutinin. In Chiu W, Burnett RM, Garcea RL (Eds) Structural Biology of Viruses. Oxford University Press NY, pp. 80-104.
114. Wiley DC, Wilson IA, Skehel JJ. (1981) Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289, 373-378.
115. Wiley DC, Skehel. (1987) The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56, 365-394.
116. Wiley JA, Hogan RJ, Woodland DL, Harmsen AG. (2001) Antigenspecific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. J. Immunol. 167, 3293-3299.
117. Wise HM, Foeglein A, Sun J, Dalton RM, Patel S, Howard W, Anderson EC, Barclay WS, Digard P. (2009) A complicated message Identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. J. Virol. 83, 8021-8031.
118. Wood JM. (2009) The 2009 influenza pandemic begins. Influenza Other Respi. Viruses 3, 197-198.
119. Wright PF, Neumann G, Kawaoka Y. (2007) Ortomyxoviruses. In Knipe DM, Howley PM (Eds) Fields Virology. 5th ed., Lippincott Wiliams and Wilkins, pp.1693-1741.
120. Wu F, Yuan XY, Huang WS, Chen YH. (2008) Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. Vaccine 27, 6095-6101.
121. Yewdell JW, Bennink JR, Smith GL, Moss B. (1985) Influenza A virus nucleoprotein is a major target antigen for crossreactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 82, 1785-1789.
122. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A. (2009):Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5, e1000350.
123. Zamarin D, Garcia-Sastre A, Xiao X, Wang R, Palese P. (2005) Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1.PLoS Pathog. 1, e4.